Guía de práctica clínica para el diagnóstico y tratamiento de la neumonía adquirida en la comunidad
Barra lateral del artículo
Contenido principal del artículo
Resumen
La neumonía adquirida en la comunidad (NAC) sigue siendo una causa principal de morbilidad y mortalidad en adultos. Su abordaje se centra en el reconocimiento temprano de la gravedad, la identificación de factores de riesgo para patógenos resistentes y la administración oportuna de antibióticos. Su diagnóstico es clínico, sin embargo, se apoya en imagen de tórax y en pruebas microbiológicas dirigidas según la severidad. La formulación de una Guía de Práctica Clínica (GPC) basada en evidencia resulta esencial para enfrentar las múltiples brechas en el diagnóstico, tratamiento y prevención de la NAC. Por tanto, la GPC tiene como propósito orientar la toma de decisiones clínicas sobre el diagnóstico, la evaluación, el tratamiento empírico, el seguimiento y la prevención de la NAC en adultos inmunocompetentes, con el fin de mejorar los desenlaces en salud, estandarizar la atención, reducir la variabilidad no justificada y optimizar el uso de los recursos disponibles en el sistema de salud colombiano.
Detalles del artículo
Citas
The top 10 causes of death n.d. https://www.who.int/news-room/factsheets/detail/the-top-10-causes-of-death (accessed August 18, 2025).
Ageing and health n.d. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health (accessed August 18, 2025).
Bernal Aguirre C, Carvajal Sierra H, Alvis N. Costos económicos de la infección respiratoria aguda en un municipio de Colombia. Revista Salud Uis, ISSN-e 2145-8464, ISSN 0121-0807, Vol 49, No 3, 2017, Págs 470-477 2017;49:470-7. https://doi.org/10.18273/revsal.v49n3-2017005
Martínez-Vernaza S, Mckinley E, Soto MJ, Gualtero S. Neumonía adquirida en la comunidad: una revisión narrativa. Univ Med 2018;59:1-10. https://doi.org/10.11144/Javeriana.umed59-4.neum
Buzzo AR, Roberts C, Mollinedo LG, Quevedo JM, Casas GL, Soldevilla JMS. Morbidity and mortality of pneumonia in adults in six latin american countries. International Journal of Infectious Diseases 2013;17:e673-7. https://doi.org/10.1016/j.ijid.2013.02.006
Rodríguez F, Barrera L, De La Rosa G, Dennis R, Dueñas C, Granados M, et al. The epidemiology of sepsis in Colombia: A prospective multicenter cohort study in ten university hospitals. Crit Care Med 2011;39:1675-82. https://doi.org/10.1097/CCM.0b013e318218a35e
Oliveros H, Tuta-Quintero E, Piñeros M, Guesguan A, Reyes LF. One-year survival of patients admitted for sepsis to intensive care units in Colombia. BMC Infect Dis 2024;24. https://doi.org/10.1186/s12879-024-09584-7
Isturiz RE, Luna CM, Ramirez J. Clinical and economic burden of pneumonia among adults in Latin America. International Journal of Infectious Diseases 2010;14. https://doi.org/10.1016/j.ijid.2010.02.2262
Nakagawa N, Katsurada M, Fukuda Y, Noguchi S, Horita N, Miki M, et al. Risk factors for drug-resistant pathogens in community-acquired pneumonia: systematic review and meta-analysis. European Respiratory Review 2025;34. https://doi.org/10.1183/16000617.0183-2024
Fabián N, Bautista P. Perfil clínico, epidemiológico y microbiológico de los pacientes con neumonía en un hospital de Bogotá en el periodo de 20162019 2019.
Mera Paredes PA, Quintero Pisso DA. Neumonía adquirida en la comunidad en inmunocompetentes : caracterización sociodemográfica, clínica y etiológica en un hospital de alta complejidad, Medellín - Colombia 2025.
Castro ALL, Camacho-Moreno G, Montañez-Ayala A, Varón-Vega F, Alvarez-Rodríguez JC, Valderrama-Beltrán S, et al. Invasive Pneumococcal Disease Characterization in Adults and Subgroups aged < 60 years and > 60 years in Bogota, Colombia. IJID Regions 2022;3:293-9. https://doi.org/10.1016/j.ijregi.2022.04.007
Instituto Nacional de Salud. Vigilancia por laboratorio de Streptococcus pneumoniae en Colombia 2024. INS 2024. https://doi.org/10.33610/109535kjvcpy
Castañeda-Orjuela C, Alvis-Guzmán N, Paternina AJ, De la Hoz Restrepo F. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population. Vaccine 2011;29:7644-50. https://doi.org/10.1016/j.vaccine.2011.08.006
Schwarz TF, Flamaing J, Rumke HC, Penzes J, Juergens C, Wenz A, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >65 years. Vaccine 2011;29:5195-202. https://doi.org/10.1016/j.vaccine.2011.05.031
Aguayo-Albasini JL, Flores-Pastor B, Soria-Aledo V. Sistema GRADE: Clasificación de la calidad de la evidencia y graduación de la fuerza de la recomendación. Cir Esp 2014;92:82-8. https://doi.org/10.1016/j.ciresp.2013.08.002
American Thoracic Society. American Thoracic Society Guidelines for the Management of Adults with Community-acquired Pneumonia. 2001. https://doi.org/10.1164/ajrccm.163.7.at1010
Emerman CL, Dawson N, Speroff T, Siciliano C, Effron D, Rashad F, et al. Comparison of Physician Judgment and Decision Aids for Ordering Chest Radiographs for Pneumonia in Outpatients. Cleveland: 1991. https://doi.org/10.1016/S0196-0644(05)81474-X
Hill AT, Gold PM, El Solh AA, Metlay JP, Ireland B, Irwin RS, et al. Adult Outpatients With Acute Cough Due to Suspected Pneumonia or Influenza: CHEST Guideline and Expert Panel Report. Chest 2019;155:155-67. https://doi.org/10.1016/j.chest.2018.09.016
Gentilotti E, De Nardo P, Cremonini E, Gorska A, Mazzaferri F, Canziani LM, et al. Diagnostic accuracy of point-of-care tests in acute communityacquired lower respiratory tract infections. A systematic review and metaanalysis. Clinical Microbiology and Infection 2022;28:13-22. https://doi.org/10.1016/j.cmi.2021.09.025
Ebell MH, Chupp H, Cai X, Bentivegna M, Kearney M. Accuracy of Signs and Symptoms for the Diagnosis of Community-acquired Pneumonia: A Meta-analysis. Academic Emergency Medicine 2020;27:541-53. https://doi.org/10.1111/acem.13965
Heltborg A, Mogensen CB, Skjot-Arkil H, Giebner M, Al-Masri A, Khatry UB, et al. Can clinicians identify community-acquired pneumonia on ultralow-dose CT? A diagnostic accuracy study. Scand J Trauma Resusc Emerg Med 2024;32. https://doi.org/10.1186/s13049-024-01242-w
Ukei TM, Bernstein HH, Bradley JS, Englund JA, File Jr TM, Fry AM, et al. Clinical Practice Guidelines by the infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Anesteziologie a Intenzivni Medicina 2018;30:97-8. https://doi.org/10.1093/cid/ciy866
Seo H, Cha SI, Shin KM, Lim JK, Yoo SS, Lee SY, et al. CommunityAcquired Pneumonia with Negative Chest Radiography Findings: Clinical and Radiological Features. Respiration 2019;97:508-17. https://doi.org/10.1159/000495068
Makhnevich A, Sinvani L, Cohen SL, Feldhamer KH, Zhang M, Lesser ML, et al. The clinical utility of chest radiography for identifying pneumonia: Accounting for diagnostic uncertainty in radiology reports. American Journal of Roentgenology 2019;213:1207-12. https://doi.org/10.2214/AJR.19.21521
Little BP, Gilman MD, Humphrey KL, Alkasab TK, Gibbons FK, Shepard JAO, et al. Outcome of recommendations for radiographic follow-up of pneumonia on outpatient chest radiography. American Journal of Roentgenology 2014;202:54-9, https://doi.org/10.2214/AJR.13.10888
Self WH, Courtney DM, McNaughton CD, Wunderink RG, Kline JA. High Discordance of Chest X-ray and CT for Detection of Pulmonary Opacities in ED Patients: Implications for Diagnosing Pneumonia. Am J Emerg Med 2012;31:401. https://doi.org/10.1016/j.ajem.2012.08.041
Washington L, O'Sullivan-Murphy B, Christensen JD, McAdams HP. Radiographic Imaging of Community-Acquired Pneumonia: A Case-Based Review. Radiol Clin North Am 2022;60:371-81. https://doi.org/10.1016/j.rcl.2022.01.011
Karimi E. Comparing Sensitivity of Ultrasonography and Plain Chest Radiography in Detection of Pneumonia; a Diagnos-tic Value Stud. vol. 7. 2019.
Overview | Pneumonia: diagnosis and management | Guidance | NICE n.d. https://www.nice.org.uk/guidance/ng250 (accessed September 25, 2025).
Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416. https://doi.org/10.1164/rccm.200405-644ST
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2019;200:E45-67. https://doi.org/10.1164/rccm.201908-1581ST
Cortés JA, Cuervo-Maldonado SI, Nocua-Báez LC, Valderrama MC, Sánchez EA, Saavedra A, et al. Clinical practice guideline for the management of community-acquired pneumonia. Revista Facultad de Medicina 2022;70. https://doi.org/10.15446/revfacmed.v70n2.93814
Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. New England Journal of Medicine 2015;373:415-27. https://doi.org/10.1056/NEJMoa1500245
Pneumonia n.d. https://www.who.int/health-topics/pneumonia#tab=tab_1 (accessed November 5, 2025).
Cortellaro F, Colombo S, Coen D, Duca PG. Lung ultrasound is an accurate diagnostic tool for the diagnosis of pneumonia in the emergency department. Emergency Medicine Journal 2012;29:19-23. https://doi.org/10.1136/emj.2010.101584
Amatya Y, Rupp J, Russell FM, Saunders J, Bales B, House DR. Diagnostic use of lung ultrasound compared to chest radiograph for suspected pneumonia in a resource-limited setting. Int J Emerg Med 2018;11. https://doi.org/10.1186/s12245-018-0170-2
Bourcier JE, Paquet J, Seinger M, Gallard E, Redonnet JP, Cheddadi F, et al. Performance comparison of lung ultrasound and chest x-ray for the diagnosis of pneumonia in the ED. American Journal of Emergency Medicine 2014;32:115-8. https://doi.org/10.1016/j.ajem.2013.10.003
Abu Naglah A, Auf F, Abo-naglh A, Zedan M, Al-sokromi M. Role of Transthoracic Ultrasound in Detection of Pneumonia in ICU Patients. vol. 83. 2015.
Demi L, Wolfram F, Klersy C, De Silvestri A, Ferretti VV, Muller M, et al. New International Guidelines and Consensus on the Use of Lung Ultrasound. Journal of Ultrasound in Medicine 2023;42:309-44. https://doi.org/10.1002/jum.16088
Patel KM, Ullah K, Patail H, Ahmad S. Ultrasound for Pleural Disease. Beyond a Pocket of Pleural Fluid. Ann Am Thorac Soc 2021;18:749-56. https://doi.org/10.1513/AnnalsATS.202008-948CME
Serrano DAR, Terán PP, Blancas R, Arroyo M. Pleuropulmonary and diaphragmatic ultrasound in intensive care medicine. Medicina Intensiva (English Edition) 2023;47:594-602. https://doi.org/10.1016/j.medine.2023.06.009
Haaksma ME, Smit JM, Heldeweg MLA, Nooitgedacht JS, De Grooth HJ, Jonkman AH, et al. Extended Lung Ultrasound to Differentiate between Pneumonia and Atelectasis in Critically Ill Patients: A Diagnostic Accuracy Study. Crit Care Med 2022;50:750-9. https://doi.org/10.1097/CCM.0000000000005303
Schott CK, Wetherbee E, Khosla R, Nathanson R, Williams JP, Mader MJ, et al. Current Use, Training, and Barriers to Point-of-Care Ultrasound Use in ICUs in the Department of Veterans Affairs. CHEST Critical Care 2023;1. https://doi.org/10.1016/j.chstcc.2023.100012
Jones BE, Ramirez JA, Oren E, Soni NJ, Sullivan LR, Restrepo MI, et al. Diagnosis and Management of Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2025. https://doi.org/10.1164/rccm.202507-1692ST
Loubet P, Tubiana S, Claessens YE, Epelboin L, Ficko C, Le Bel J, et al. Community-acquired pneumonia in the emergency department: an algorithm to facilitate diagnosis and guide chest CT scan indication. Clinical Microbiology and Infection 2020;26:382.e1-382.e7. https://doi.org/10.1016/j.cmi.2019.06.026
Claessens YE, Debray MP, Tubach F, Brun AL, Rammaert B, Hausfater P, et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med 2015;192:974-82. https://doi.org/10.1164/rccm.201501-0017OC
Ibrahim D, Rahman Bizri A, Ali M, Amine E, Halabi Z. Chest computed tomography and chest X-ray in the diagnosis of community-acquired pneumonia: a retrospective observational study n.d. https://doi.org/10.1177/03000605211039791
Van Engelen TSR, Kanglie MMNP, Van Den Berk IAH, Altenburg J, Dijkgraaf MGW, Bossuyt PMM, et al. Limited Clinical Impact of Ultralow-Dose Computed Tomography in Suspected Community-Acquired Pneumonia 2023. https://doi.org/10.1093/ofid/ofad215
Niederman MS. Imaging for the Management of Community-Acquired Pneumonia What to Do if the Chest Radiograph Is Clear. Chest 2018;153:583-5. https://doi.org/10.1016/j.chest.2017.09.045
Garin N, Marti C, Scheffler M, Stirnemann J, Prendki V. Computed tomography scan contribution to the diagnosis of community-acquired pneumonia. Curr Opin Pulm Med 2019;25:242-8. https://doi.org/10.1097/MCP.0000000000000567
Upchurch CP, Grijalva CG, Wunderink RG, Williams DJ, Waterer GW, Anderson EJ, et al. Community-Acquired Pneumonia Visualized on CT Scans but Not Chest Radiographs: Pathogens, Severity, and Clinical Outcomes. Chest 2018;153:601-10. https://doi.org/10.1016/j.chest.2017.07.035
Biancolin SE, dos Santos Fernandes H, Sawamura MVY, Queiroz J, Centofanti SF, Liao AW, et al. Lung ultrasound versus chest computed tomography for pregnant inpatients with COVID-19. Journal of Clinical Ultrasound 2023;51:54-63. https://doi.org/10.1002/jcu.23286
Shiley KT, Van Deerlin VM, Miller WT. Chest CT Features of Communityacquired Respiratory Viral Infections in Adult Inpatients With Lower Respiratory Tract Infections. vol. 25. 2010. https://doi.org/10.1097/ RTI.0b013e3181b0ba8b.
Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults. 2000. https://doi.org/10.1086/313954
Elien Dinh A, Barbier F, Bedos J-P, Blot M, Cattoir V, Claessens Y-E, et al. Update of guidelines for management of Community Acquired pneumonia in adults by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF). Respir Med Res 2025;87:101161. https://doi.org/10.1016/j.resmer.2025.101161
Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High-Resolution Computed Tomography for the Diagnosis of Community-Acquired Pneumonia. 1998. https://doi.org/10.1086/514675
Chen M, Zeng SY, Lu SJ, Shi M, Zhang QQ. Early re-examination of chest CT may be unnecessary when patients with psittaci pneumonia at low and intermediate risk on Pneumonia Severity Index present with response to initial treatment. Front Med (Lausanne) 2025;12. https://doi.org/10.3389/fmed.2025.1574706
García- Vaszquez E, Marcos MA, Mensa J, de Roux A, Puig J, Font C, et al. Assessment of the Usefulness of Sputum Culture for Diagnosis of Community-Acquired Pneumonia Using the PORT Predictive Scoring System. 2004. https://doi.org/10.1001/archinte.164.16.1807
Del Rio-Pertuz G, Gutiérrez JF, Triana AJ, Molinares JL, Robledo-Solano AB, Meza JL, et al. Usefulness of sputum gram stain for etiologic diagnosis in community-acquired pneumonia: A systematic review and meta-analysis. BMC Infect Dis 2019;19. https://doi.org/10.1186/s12879-019-4048-6
Ewig S, Schlochtermeier M, Gooke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: Limited yield, minimal impact on treatment decisions. Chest 2002;121:1486-92. https://doi.org/10.1378/chest.121.5.1486
Theerthakarai R, El-Halees W, Ismail M, Solis RA, Khan MA. Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest 2001;119:181-4. https://doi.org/10.1378/chest.119.1.181
Levy M, Dromer F, Brion N, Leturdu F, Carbon C. Community-acquired pneumonia. Importance of initial noninvasive bacteriologic and radiographic investigations. Chest 1988;93:43-8. https://doi.org/10.1378/chest.93.1.43
Shariatzadeh MR, Marrie TJ. Does sputm culture affect the management and or outcome of community acquired pneumonia? vol. 15. 2009. https://doi.org/10.26719/2009.15.4.792
Roson B, Carratala J, Verdaguer R, Dorca J, Manresa F, Gudiol F. Prospective Study of the Usefulness of Sputum Gram Stain in the Initial Approach to Community-Acquired Pneumonia Requiring Hospitalization. 2000. https://doi.org/10.1086/318151
Musher DM, Montoya R, Wanahita A. Diagnostic Value of Microscopic Examination of Gram-Stained Sputum and Sputum Cultures in Patients with Bacteremic Pneumococcal Pneumonia Downloaded from. vol. 165. 2004. https://doi.org/10.1086/421497
Bartlett JG. Diagnostic test for etiologic agents of communityacquired pneumonia. Infect Dis Clin North Am 2005;18:809. https://doi.org/10.1016/j.idc.2004.08.002
Lee YJ, Shin S, Roh EY, Yoon JH, Kim DK, Chung HS, et al. Acceptability of sputum specimens for diagnosing pulmonary tuberculosis. J Korean Med Sci 2015;30:733-6. https://doi.org/10.3346/jkms.2015.30.6.733
Murray PR, Washington JA. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc 1975:339-334. https://doi.org/10.1016/S0025-6196(25)09678-8
Musher DM, Roig IL, Cazares G, Stager CE, Logan N, Safar H. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: Results of a one-year study. Journal of Infection 2013;67:11-8. https://doi.org/10.1016/j.jinf.2013.03.003
Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: A prospective observational study. Chest 2003;123:1142-50. https://doi.org/10.1378/chest.123.4.1142
Erdede M, Denizbasi A, Onur O, Guneysel O. Do we really need blood cultures in treating patients with community-acquired pneumonia ? Bratislava Medical Journal 2010.
Chalasani NP, Valdecanas MAL, Gopal AK, McGowan JE, Jurado RL. Clinical utility of blood cultures in adult patients with community- acquired pneumonia without defined underlying risks. Chest 1995;108:932-6. https://doi.org/10.1378/chest.108.4.932
Van Werkhoven CH, Huijts SM, Postma DF, Oosterheert JJ, Bonten MJM. Predictors of Bacteraemia in Patients with Suspected CommunityAcquired Pneumonia. PLoS One 2015;10:e0143817. https://doi.org/10.1371/journal.pone.0143817
Chambers DC, Waterer GW. Are blood cultures necessary in communityacquired pneumonia? Clin Pulm Med 2005;12:146-52. https://doi.org/10.1097/01.cpm.0000163189.23997.f0
Zhang D, Yang D, Makam AN. Utility of Blood Cultures in Pneumonia. American Journal of Medicine 2019;132:1233-8. https://doi.org/10.1016/j.amjmed.2019.03.025
Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gonzalez MD, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clinical Infectious Diseases 2024. https://doi.org/10.1093/cid/ciae104
Pickens C, Wunderink RG, Qi C, Mopuru H, Donnelly H, Powell K, et al. A multiplex polymerase chain reaction assay for antibiotic stewardship in suspected pneumonia. Diagn Microbiol Infect Dis 2020;98. https://doi.org/10.1016/j.diagmicrobio.2020.115179
Virk A, Strasburg AP, Kies KD, Donadio AD, Mandrekar J, Harmsen WS, et al. Rapid multiplex PCR panel for pneumonia in hospitalised patients with suspected pneumonia in the USA: a single-centre, open-label, pragmatic, randomised controlled trial. Lancet Microbe 2024;5:100928. https://doi.org/10.1016/S2666-5247(24)00170-8
Monard C, Pehlivan J, Auger G, Alviset S, Tran Dinh A, Duquaire P, et al. Multicenter evaluation of a syndromic rapid multiplex PCR test for early adaptation of antimicrobial therapy in adult patients with pneumonia. Crit Care 2020;24. https://doi.org/10.1186/s13054-020-03114-y
Templeton KE, Scheltinga SA, Van Den Eeden WCJFM, Graffelman AW, Van Den Broek PJ, Claas ECJ. Improved diagnosis of the etiology of communityacquired pneumonia with real-time polymerase chain reaction. Clinical Infectious Diseases 2005;41:345-51. https://doi.org/10.1086/431588
Hohenthal U, Vainionpaa R, Meurman O, Vahtera A, Katiskalahti T, Nikoskelainen J, et al. Aetiological diagnosis of community acquired pneumonia: Utility of rapid microbiological methods with respect to disease severity. Scand J Infect Dis 2008;40:131-8. https://doi.org/10.1080/00365540701534525
Holter JC, Muller F, Bjorang O, Samdal HH, Marthinsen JB, Jenum PA, et al. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: A 3-year prospective study in Norway. BMC Infect Dis 2015;15. https://doi.org/10.1186/s12879-015-0803-5
McCauley LM, Webb BJ, Sorensen J, Dean NC. Use of tracheal aspirate culture in newly intubated patients with community-onset pneumonia. Ann Am Thorac Soc 2016;13:376-81. https://doi.org/10.1513/AnnalsATS.201506-368BC
Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med 2023;49:615-32. https://doi.org/10.1007/s00134-023-07033-8
Molina FJ, Botero LE, Isaza JP, Cano LE, López L, Tamayo L, et al. Diagnostic concordance between BioFire® FilmArray® Pneumonia Panel and culture in patients with COVID-19 pneumonia admitted to intensive care units: the experience of the third wave in eight hospitals in Colombia. Crit Care 2022;26. https://doi.org/10.1186/s13054-022-04006-z
Andreo F, Dominguez J, Ruiz J, Blanco S, Arellano E, Prat C, et al. Impact of rapid urine antigen tests to determine the etiology of communityacquired pneumonia in adults. Respir Med 2006;100:884-91. https://doi.org/10.1016/j.rmed.2005.08.020
Piso RJ, Iven-Koller D, Koller MT, Bassetti S. The routine use of the urinary pneumococcal antigen test in hospitalised patients with community acquired pneumonia has limited impact for adjustment of antibiotic treatment. Swiss Med Wkly 2012;142. https://doi.org/10.4414/smw.2012.13679
Johansson N, Kalin M, Annika TL, Giske CG, Hedlund J. Etiology of Community-Acquired pneumonia: Increased microbiological yield with new diagnostic methods. Clinical Infectious Diseases 2010;50:202-9. https://doi.org/10.1086/648678
Riaño-Sánchez LF, Alvarez-Moreno CA, Godoy M, Sierra CR, Castañeda MI, Cortés JA. Multiplex PCR Pneumonia Panel in Critically Ill Patients Did Not Modify Mortality: A Cohort Study. Antibiotics (Basel) 2025;14. https://doi.org/10.3390/antibiotics14030245
Espinosa O, Bejarano V, Franky I, Pagali S, Drummond M, Franco OH. Mortality causes and health spending by gender and health conditions in octogenarians, nonagenarians and centenarians in Colombia. Sci Rep 2025;15:1-8. https://doi.org/10.1038/s41598-024-84150-4
Remolina YA, Ulloa MM, Vargas H, Díaz L, Gómez SL, Saavedra A, et al. Viral Infection in Adults with Severe Acute Respiratory Infection in Colombia. PLoS One 2015;10. https://doi.org/10.1371/journal.pone.0143152
Falsey AR, Becker KL, Swinburne AJ, Nylen ES, Formica MA, Hennessey PA, et al. Bacterial complications of respiratory tract viral illness: A comprehensive evaluation. Journal of Infectious Diseases 2013;208:432-41. https://doi.org/10.1093/infdis/jit190
Johnstone J, Majumdar SR, Fox JD, Marne TJ. Original Research Viral Infection in Adults Hospitalized With Community-Acquired Pneumonia* Prevalence, Pathogens, and Presentation n.d. https://doi.org/10.1378/chest.08-0888
Das D, Le Floch H, Houhou N, Epelboin L, Hausfater P, Khalil A, et al. Viruses detected by systematic multiplex polymerase chain reaction in adults with suspected community-acquired pneumonia attending emergency departments in France. Clinical Microbiology and Infection 2015;21:608.e1-608.e8. https://doi.org/10.1016/j.cmi.2015.02.014
Oosterheert JJ, Van Loon AM, Schuurman R, Hoepelman AIM, Hak E, Thijsen S, et al. Impact of Rapid Detection of Viral and Atypical Bacterial Pathogens by Real-Time Polymerase Chain Reaction for Patients with Lower Respiratory Tract Infection. 2005. https://doi.org/10.1086/497134
Chartrand C, Leeflang MMG, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med 2012;156:500-11. https://doi.org/10.7326/0003-4819-156-7-201204030-00403
Merckx J, Wali R, Schiller I, Caya C, Gore GC, Chartrand C, et al. Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction: A Systematic Review and Meta-analysis. Ann Intern Med 2017;167:395-409. https://doi.org/10.7326/M17-0848
Uyeki TM, Hui DS, Zambon M, Wentworth DE, Monto AS. Influenza. 2022. https://doi.org/10.1016/S0140-6736(22)00982-5
Bruning AHL, Leeflang MMG, Vos JMBW, Spijker R, De Jong MD, Wolthers KC, et al. Rapid Tests for Influenza, Respiratory Syncytial Virus, and Other Respiratory Viruses: A Systematic Review and Meta-analysis. Clin Infect Dis 2017;65:1026-32. https://doi.org/10.1093/cid/cix461
Harris AM, Bramley AM, Jain S, Arnold SR, Ampofo K, Self WH, et al. Influence of antibiotics on the detection of bacteria by culture-based and culture-independent diagnostic tests in patients hospitalized with community-acquired pneumonia. Open Forum Infect Dis 2017;4. https://doi.org/10.1093/ofid/ofx014
Cattoir V, Dinh A, Jarraud S, Monnier A Le, Loubet P. Value of molecular biology tests in community-acquired acute pneumonia. Infect Dis Now 2025;55. https://doi.org/10.1016/j.idnow.2025.105128
Jimenez P, Saldias F, Meneses M, Silva ME, Wilson MG, Otth L. Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia; Comparison between bronchoalveolar lavage and telescoping plugged catheter cultures. Chest 1993;103:1023-7. https://doi.org/10.1378/chest.103.4.1023
Ortqvist A, Kalin M, Lejdeborn L, Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with communityacquired pneumonia. Chest 1990;97:576-82. https://doi.org/10.1378/chest.97.3.576
Manali E, Papadopoulos A, Tsiodras S, Polychronopoulos V, Giamarellou H, Kanellakopoulou K. The impact on community acquired pneumonia empirical therapy of diagnostic bronchoscopic techniques. Scand J Infect Dis 2008;40:286-92. https://doi.org/10.1080/00365540701663373
Rea-Neto A, Youssef NCM, Tuche F, Brunkhorst F, Marco VM, Reinhart K, et al. Diagnosis of ventilator-associated pneumonia: a systematic review of the literature. Crit Care 2008;12:R56. https://doi.org/10.1186/cc6877
Lim WS, Baudouin S, George R, Hill A, Jamieson C, Le Jeune I, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: Update 2009. Thorax 2009;64. https://doi.org/10.1136/thx.2009.121434
Bravo Jover RM, Gil-Guillen VF, Pérez Barba C, Quesada JA, García López M, García Soriano I, et al. Factors Associated with Complicated Parapneumonic Pleural Effusion/Empyema in Patients with CommunityAcquired Pneumonia: The EMPIR Study. J Clin Med 2025;14:1739. https://doi.org/10.3390/jcm14051739
Zaki HA, Bensliman S, Bashir K, Iftikhar H, Fayed MH, Salem W, et al. Accuracy of procalcitonin for diagnosing sepsis in adult patients admitted to the emergency department: a systematic review and meta-analysis. Syst Rev 2024;13. https://doi.org/10.1186/s13643-023-02432-w
Self WH, Balk RA, Grijalva CG, Williams DJ, Zhu Y, Anderson EJ, et al. Procalcitonin as a Marker of Etiology in Adults Hospitalized with Community-Acquired Pneumonia. Clinical Infectious Diseases 2017;65:183-90. https://doi.org/10.1093/cid/cix317
Huang DT, Yealy DM, Filbin MR, Brown AM, Chang C-CH, Doi Y, et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. New England Journal of Medicine 2018;379:236-49. https://doi.org/10.1056/NEJMoa1802670
Christ-crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and autcome in lower respiratory tract infections: cluster-randomised, singleblinded intervention trial. The Lancet 2004;363. https://doi.org/10.1016/S0140-6736(04)15591-8
Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews 2017;2017. https://doi.org/10.1002/14651858.CD007498.pub3
Tuta-Quintero E, Goyes ARB, Guerrón-Gómez G, Martínez MC, Torres D, Schloss C, et al. Comparison of performances between risk scores for predicting mortality at 30 days in patients with community acquired pneumonia. BMC Infect Dis 2024;24. https://doi.org/10.1186/s12879-024-09792-1
Tuta-Quintero E, Bastidas AR, Guerrón-Gómez G, Perna-Reyes I, Torres D, Garcia L, et al. Performance of risk scores in predicting mortality at 3, 6, and 12 months in patients diagnosed with community-acquired pneumonia. BMC Pulm Med 2024;24. https://doi.org/10.1186/s12890-024-03121-7
Tuta-Quintero E, Bastidas AR, Mora A, Reyes LF, Bello LE, Nonzoque AP, et al. Comparison of the Predictive Capacity of Oxygenation Parameters, Oxygenation Indices, and CURB-65 to Mortality, Mechanical Ventilation, and Vasopressor Support in Community-Acquired Pneumonia at Different Altitudes. Can Respir J 2025;2025. https://doi.org/10.1155/carj/9378618
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community acquired pneumonia. 1997. https://doi.org/10.1056/NEJM199701233360402
Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. American Journal of Medicine 2005;118:384-92. https://doi.org/10.1016/j.amjmed.2005.01.006
Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A Controlled Trial of a Critical Pathway for Treatment of CommunityAcquired Pneumonia. 2000. https://doi.org/10.1001/jama.283.6.749
Jones BE, Jones J, Bewick T, Lim WS, Aronsky D, Brown SM, et al. CURB-65 pneumonia severity assessment adapted for electronic decision support. Chest 2011;140:156-63. https://doi.org/10.1378/chest.10-1296
Charles P, Wolfe R, Whitby M, Fine MJ, Fuller A, Stirling R, et al. SMARTCOP: a tool for predicting the need for intensive respiratory or vasopresor support in community-acquired pneumonia. Clin Infect Dis 2008;47:375-84. https://doi.org/10.1086/589754
Phua J, See KC, Chan YH, Widjaja LS, Aung NW, Ngerng WJ, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009;64:598-603. https://doi.org/10.1136/thx.2009.113795
Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ 2020;370. https://doi.org/10.1136/bmj.m3339
Crocker-Buque T, Myles J, Brentnall A, Gabe R, Duffy S, Williams S, et al. Using ISARIC 4C mortality score to predict dynamic changes in mortality risk in COVID-19 patients during hospital admission. PLoS One 2022;17. https://doi.org/10.1371/journal.pone.0274158
Koh LP, Chia TRT, Wang SSY, Chavatte JM, Hawkins R, Ting Y, et al. Utility of ISARIC 4C Mortality Score, Vaccination History, and Anti-S Antibody Titre in Predicting Risk of Severe COVID-19. Viruses 2024;16. https://doi.org/10.3390/v16101604
Andrea Gallego Aristizabal P, Paola Lujan Chavarría T, Isabel Vergara Hernández S, Rincón Acosta F, Paula Sánchez Carmona M, Andrea Salazar Ospina P, et al. External validation of two clinical prediction models for mortality in COVID-19 patients (4C and NEWS2), in three centers in Medellín, Colombia: Assessing the impact of vaccination over time. Infect Dis Now 2024;54. https://doi.org/10.1016/j.idnow.2024.104921
Eapen S, Llop C, Tuttle E. 810: Antibiotic Treatment Patterns and Outcomes Following Outpatient Treatment of Community-Acquired Bacterial Pneumonia: A US Cohort Study. Open Forum Infect Dis 2014;1:S230. https://doi.org/10.1093/ofid/ofu052.518
Robledo J, Sierra P, Bedoya F, Londoño A, Porras A, Luján M, et al. Neumonías adquiridas en la comunidad en adultos: Un estudio etiológico prospectivo con énfasis en el diagnóstico. Revista Colombiana de Neumologia n.d.;15.
Caballero A, Polania E, Gordillo M, Martinez O, Torrado E, Lagos M, et al. Agentes etiológicos de la neumonía adquirida en la comunidad (NAC) en pacientes adultos inmunocompetentes que consultan al servicio de urgencias de la Clínica Reina Sofìa Bogotá, 2006-2007 2010;13.
Womack J, Kropa J. Community-Acquired Pneumonia in Adults: Rapid Evidence Review. Am Fam Physician 2022;105:625-30.
Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. American Journal of Medicine 2005;118:21-8. https://doi.org/10.1016/j.amjmed.2005.05.010
Pakhale S, Mulpuru S, Verheij TJM, Kochen MM, Rohde GGU, Bjerre LM. Antibiotics for community-acquired pneumonia in adult outpatients. Cochrane Database of Systematic Reviews 2014;2014. https://doi.org/10.1002/14651858.CD002109.pub4
Tan JS, File TM. Management of community-acquired pneumonia: A focus on conversion from hospital to the ambulatory setting. American Journal of Respiratory Medicine 2003;2:385-94. https://doi.org/10.1007/BF03256666
Petitpretz P, Arvis P, Marel M, Moita J, Urueta J, Jasovich J, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-tomoderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185-95. https://doi.org/10.1378/chest.119.1.185
Dalovisio JR. Overview of Lower Respiratory Tract Infections: Diagnosis and Treatment. Ochsner J 2002;4:227.
Matuz M, Bognar J, Hajdu E, Doro P, Bor A, Viola R, et al. Treatment of Community-Acquired Pneumonia in Adults: Analysis of the National Dispensing Database. Basic Clin Pharmacol Toxicol 2015;117:330-4. https://doi.org/10.1111/bcpt.12426
Bonvehi P, Weber K, Busman T, Shortridge D, Notario G. Comparison of clarithromycin and amoxicillin/clavulanic acid for community-acquired pneumonia in an era of drug-resistant Streptococcus pneumoniae. Clin Drug Investig 2003;23:491-501. https://doi.org/10.2165/00044011-200323080-00001
Fogarty C, Siami G, Kohler R, File TM, Tennenberg AM, Olson WH, et al. Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Levofloxacin versus Ceftriaxone Sodium and Erythromycin Followed by Clarithromycin and Amoxicillin-Clavulanate in the Treatment of Serious Community-Acquired Pneumonia in Adults. 2004. https://doi.org/10.1086/378406
Prosty C, Noutsios D, Lee TC, Daneman N, Davis JS, Jager NGL, et al. Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillinsusceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. Clinical Microbiology and Infection 2025;31:1272-82. https://doi.org/10.1016/j.cmi.2025.04.045
Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-Resistant Pathogens Associated With HealthcareAssociated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol 2016;37:1288-301. https://doi.org/10.1017/ice.2016.174
Postma DF, van Werkhoven CH, van Elden LJR, Thijsen SFT, Hoepelman AIM, Kluytmans JAJW, et al. Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults. New England Journal of Medicine 2015;372:1312-23. https://doi.org/10.1056/NEJMoa1406330
Vardakas KZ, Trigkidis KK, Falagas ME. Fluoroquinolones or macrolides in combination with B-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clinical Microbiology and Infection 2017;23:234-41. https://doi.org/10.1016/j.cmi.2016.12.002
Mukae H, Iwanaga N, Horita N, Komiya K, Maruyama T, Shindo Y, et al. The JRS guideline for the management of pneumonia in adults 2024. Respir Investig 2025;63:811-28. https://doi.org/10.1016/j.resinv.2025.06.014
Viasus D, Simonetti AF, Garcia-Vidal C, Niubo J, Dorca J, Carratala J. Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. Journal of Antimicrobial Chemotherapy 2017;72:547-53. https://doi.org/10.1093/jac/dkw441
Rothe K, Spinner CD, Panning M, Pletz MW, Rohde G, Rupp J, et al. Evaluation of a multiplex PCR screening approach to identify communityacquired bacterial co-infections in COVID-19: a multicenter prospective cohort study of the German competence network of communityacquired pneumonia (CAPNETZ). Infection 2021;49:1299-306. https://doi.org/10.1007/s15010-021-01720-8
Buchan BW, Windham S, Balada-Llasat JM, Leber A, Harrington A, Relich R, et al. Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections. J Clin Microbiol 2020;58. https://doi.org/10.1128/JCM.00135-20
Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia a systematic review. JAMA - Journal of the American Medical Association 2016;315:593-602. https://doi.org/10.1001/jama.2016.0115
Nie W, Li B, Xiu Q. B-Lactam/macrolide dual therapy versus B-lactam monotherapy for the treatment of community-acquired pneumonia in adults: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy 2014;69:1441-6. https://doi.org/10.1093/jac/dku033
Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, et al. Beta-lactam plus macrolides or beta-lactam alone for communityacquired pneumonia: A systematic review and meta-analysis. Respirology 2016;21:1193-200. https://doi.org/10.1111/resp.12835
Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, Doulou S, Kakavoulis N, Tsiakos K, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2024;12:294-304. https://doi.org/10.1016/S2213-2600(23)00412-5
Cilloniz C, Gabarrus A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, et al. Community-Acquired Pneumonia Due to Multidrug- and Non- Multidrug-Resistant Pseudomonas aeruginosa. Chest 2016;150:415-25. https://doi.org/10.1016/j.chest.2016.03.042
Pascual-Guardia S, Amati F, Marin-Corral J, Aliberti S, Gea J, Soni NJ, et al. Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia. Arch Bronconeumol 2023;59:90-100. https://doi.org/10.1016/j.arbres.2022.09.005
Miravitlles M, Mayordomo C, Artes M, Sanchez-Agudo L, Nicolau F, Segu JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med 1999;93:173-9. https://doi.org/10.1016/S0954-6111(99)90004-5
Eller J, Ede A, Schaberg T, Niederman M, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998;113:43-8. https://doi.org/10.1378/chest.113.6.1542
Ishida T, Ito A, Washio Y, Yamazaki A, Noyama M, Tokioka F, et al. Risk factors for drug-resistant pathogens in immunocompetent patients with pneumonia: Evaluation of PES pathogens. Journal of Infection and Chemotherapy 2017;23:23-8. https://doi.org/10.1016/j.jiac.2016.09.002
Wijit K, Sonthisombat P, Diewsurin J. A score to predict Pseudomonas aeruginosa infection in older patients with community-acquired pneumonia. BMC Infect Dis 2023;23. https://doi.org/10.1186/s12879-023-08688-w
Metersky ML, Frei CR, Mortensen EM. Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia. Respirology 2016;21:157-63. https://doi.org/10.1111/resp.12651
Jones BE, Ying J, Stevens V, Haroldsen C, He T, Nevers M, et al. Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia. JAMA Intern Med 2020;180:552-60. https://doi.org/10.1001/jamainternmed.2019.7495
Rothberg MB, Zilberberg MD, Pekow PS, Priya A, Haessler S, Belforti R, et al. Association of guideline-based antimicrobial therapy and outcomes in healthcare-associated pneumonia. Journal of Antimicrobial Chemotherapy 2014;70:1573-9. https://doi.org/10.1093/jac/dku533
Prina E, Ranzani OT, Polverino E, Cilloniz C, Ferrer M, Fernandez L, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 2015;12:153-60. https://doi.org/10.1513/AnnalsATS.201407-305OC
Gonzalez-C CL, Calia FM. Bacteriologic flora of aspiration-induced pulmonary infections. Arch Intern Med 1975;135:711-4. https://doi.org/10.1001/archinte.135.5.711
Treatment of aspiration pneumonia and primary lung abscess. Penicillin G vs clindamycin - PubMed n.d. https://pubmed.ncbi.nlm.nih.gov/1041750/ (accessed September 7, 2025).
El-Solh AA, Pietrantoni C, Bhat A, Aquilina AT, Okada M, Grover V, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003;167:1650-4. https://doi.org/10.1164/rccm.200212-1543OC
Marik PE, Carcan P. The role of anaerobes in patients with ventilatorassociated pneumonia and aspiration pneumonia: A prospective study. Chest 1999;115:178-83. https://doi.org/10.1378/chest.115.1.178
Yoshimatsu Y, Aga M, Komiya K, Haranaga S, Numata Y, Miki M, et al. The Clinical Significance of Anaerobic Coverage in the Antibiotic Treatment of Aspiration Pneumonia: A Systematic Review and Meta-Analysis. J Clin Med 2023;12. https://doi.org/10.3390/jcm12051992
Bai AD, Srivastava S, Digby GC, Girard V, Razak F, Verma AA. Anaerobic Antibiotic Coverage in Aspiration Pneumonia and the Associated Benefits and Harms: A Retrospective Cohort Study. Chest 2024;166:39-48. https://doi.org/10.1016/j.chest.2024.02.025
Tieying S, Li S, Rongmei Wang, Xiaoping Ren, Dong-Jiang Sui, Chun Pu, et al. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors - PubMed 2014. https://pubmed.ncbi.nlm.nih.gov/24709166/ (accessed September 7, 2025).
Hasegawa S, Shiraishi A, Yaegashi M, Hosokawa N, Morimoto K, Mori T. Ceftriaxone versus ampicillin/sulbactam for the treatment of aspirationassociated pneumonia in adults. J Comp Eff Res 2019;8:1275-84. https://doi.org/10.2217/cer-2019-0041
Mandell LA, Niederman MS. Aspiration Pneumonia. N Engl J Med 2019;380:651-63. https://doi.org/10.1056/NEJMra1714562
Bowerman TJ, Zhang J, Waite LM. Antibacterial treatment of aspiration pneumonia in older people: A systematic review. Clin Interv Aging 2018;13:2201-13. https://doi.org/10.2147/CIA.S183344
Kadowaki M, Demura Y, Mizuno Shiro, Uesaka D, Ameshima S, Miyamori I, et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-tomoderate aspiration pneumonia in elderly patients. Chest 2005;127:1276. https://doi.org/10.1378/chest.127.4.1276
Levison ME, Mangura CT, Lorber B, Abrutyn E, Pesanti EL, Levy RS, et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann Intern Med 1983;98:466-71. https://doi.org/10.7326/0003-4819-98-4-466
Marras TK, Nopmaneejumruslers C, Chan CKN. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere communityacquired pneumonia: A retrospective study and meta-analysis. American Journal of Medicine 2004;116:385-93. https://doi.org/10.1016/j.amjmed.2003.11.013
Lee RWW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology 2007;12:111-6. https://doi.org/10.1111/j.1440-1843.2006.00931.x
Dinh A, Duran C, Ropers J, Bouchand F, Deconinck L, Matt M, et al. Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trial. Clin Microbiol Infect 2024;30:1020-8. https://doi.org/10.1016/j.cmi.2024.05.003
Nathan R V., Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR. In-Hospital Observation After Antibiotic Switch in Pneumonia: A National Evaluation. American Journal of Medicine 2006;119. https://doi.org/10.1016/j.amjmed.2005.09.012
Aliberti S, Peyrani P, Filardo G, Mirsaeidi M, Amir A, Blasi F, et al. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest 2011;140:482-8. https://doi.org/10.1378/chest.10-2895
Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Scott Obrosky D, et al. Time to Clinical Stability in Patients Hospitalized With CommunityAcquired Pneumonia Implications for Practice Guidelines. 1998. https://doi.org/10.1001/jama.279.18.1452
El Moussaoui R, De Borgie CAJM, Van Den Broek P, Hustinx WN, Bresser P, Van Den Berk GEL, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. 2006. https://doi.org/10.1136/bmj.332.7554.1355
Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, et al. High-Dose, Short-Course Levofloxacin for CommunityAcquired Pneumonia: A New Treatment Paradigm. vol. 37. 2003. https://doi.org/10.1086/377539
Furukawa Y, Luo Y, Funada S, Onishi A, Ostinelli E, Hamza T, et al. Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis. BMJ Open 2023;13. https://doi.org/10.1136/bmjopen-2022-061023
Kuijpers SME, Buis DTP, Ziesemer KA, van Hest RM, Schade RP, Sigaloff KCE, et al. The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrela review. Lancet Infect Dis 2025;25:94-113. https://doi.org/10.1016/S1473-3099(24)00456-0
Tansarli GS, Mylonakis E. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults. Antimicrob Agents Chemother 2018;62. https://doi.org/10.1128/AAC.00635-18
Vaughn VM, Flanders SA, Snyder A, Conlon A, Rogers MAM, Malani AN, et al. Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: A multihospital cohort study. Ann Intern Med 2019;171:153-63. https://doi.org/10.7326/M18-3640
Smit JM, Van Der Zee PA, Stoof SCM, Van Genderen ME, Snijders D, Boersma WG, et al. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven análisis of randomised trials. Lancet Respir Med 2025;13:221-33. https://doi.org/10.1016/S2213-2600(24)00405-3
Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. JAMA - Journal of the American Medical Association 2015;313:677-86. https://doi.org/10.1001/jama.2015.88
Fernández-Serrano S, Dorca J, Garcia-Vidal C, Fernández-Sabe N, Carratala J, Fernández-Aguera A, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: A randomized controlled trial. Crit Care 2011;15. https://doi.org/10.1186/cc10103
Siemieniuk RAC, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid therapy for patients hospitalized with communityacquired pneumonia: A systematic review and metaanalysis. Ann Intern Med 2015;163:519-28. https://doi.org/10.7326/M15-0715
Dequin P-F, Meziani F, Quenot J-P, Kamel T, Ricard J-D, Badie J, et al. Hydrocortisone in Severe Community-Acquired Pneumonia. New England Journal of Medicine 2023;388:1931-41. https://doi.org/10.1056/NEJMoa2215145
Heming N, Renault A, Kuperminc E, Brun-Buisson C, Megarbane B, Quenot JP, et al. Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial. Lancet Respir Med 2024;12:366-74. https://doi.org/10.1016/S2213-2600(23)00430-7
Schultz MJ, Roca O, Shrestha GS. Global lessons learned from COVID-19 mass casualty incidents. Br J Anaesth 2022;128:e97-100. https://doi.org/10.1016/j.bja.2021.10.040
The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine 2021;384:693- 704. https://doi.org/10.1056/NEJMoa2021436
Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database of Systematic Reviews 2016;2016. https://doi.org/10.1002/14651858.CD010406.pub2
Parke RL, McGuinness SP, Eccleston ML. A Preliminary Randomized Controlled Trial to Assess Effectiveness of Nasal High-Flow Oxygen in Intensive Care Patients. Https://HomeLiebertpubCom/Rcare 2011;56:265- 70. https://doi.org/10.4187/respcare.00801
Sztrymf B, Messika J, Bertrand F, Hurel D, Leon R, Dreyfuss D, et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: A prospective pilot study. Intensive Care Med 2011;37:1780-6. https://doi.org/10.1007/s00134-011-2354-6
Moller W, Celik G, Feng S, Bartenstein P, Meyer G, Eickelberg O, et al. Nasal high flow clears anatomical dead space in upper airway models. J Appl Physiol 2015;118:1525-32. https://doi.org/10.1152/japplphysiol.00934.2014
Moller W, Feng S, Domanski U, Franke KJ, Celik G, Bartenstein P, et al. Nasal high flow reduces dead space. J Appl Physiol 2017;122:191-7. https://doi.org/10.1152/japplphysiol.00584.2016
Parke RL, McGuinness SP. Pressures Delivered By Nasal High Flow Oxygen During All Phases of the Respiratory Cycle. Https://HomeLiebertpubCom/Rcare 2013;58:1621-4. https://doi.org/10.4187/respcare.02358
Frat J-P, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. HighFlow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. New England Journal of Medicine 2015;372:2185-96. https://doi.org/10.1056/NEJMoa1503326
Grieco DL, Menga LS, Raggi V, Bongiovanni F, Anzellotti GM, Tanzarella ES, et al. Physiological Comparison of High-Flow Nasal Cannula and Helmet Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure. 2020;201:303-12. https://doi.org/10.1164/rccm.201904-0841OC
Confalonieri M, Potena A, Carbone G, Porta R Della, Tolley EA, Meduri GU. Acute Respiratory Failure in Patients with Severe Community-acquired Pneumonia A Prospective Randomized Evaluation of Noninvasive Ventilation. vol. 160. 1999. https://doi.org/10.1164/ajrccm.160.5.9903015
Lemiale V, Mokart D, Resche-Rigon M, Pene F, Mayaux J, Faucher E, et al. Effect of Noninvasive Ventilation vs Oxygen Therapy on Mortality Among Immunocompromised Patients With Acute Respiratory Failure: A Randomized Clinical Trial. JAMA 2015;314:1711-9. https://doi.org/10.1001/jama.2015.12402
Brambilla AM, Aliberti S, Prina E, Nicoli F, Forno M Del, Nava S, et al. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia. Intensive Care Med 2014;40:942-9. https://doi.org/10.1007/s00134-014-3325-5
Cosentini R, Brambilla AM, Aliberti S, Bignamini A, Nava S, Maffei A, et al. Helmet Continuous Positive Airway Pressure vs Oxygen Therapy To Improve Oxygenation in Community-Acquired Pneumonia: A Randomized, Controlled Trial. Chest 2010;138:114-20. https://doi.org/10.1378/chest.09-2290
Tobin MJ, Laghi F, Jubran A. P-SILI is not justification for intubation of COVID-19 patients. Ann Intensive Care 2020;10:1-2. https://doi.org/10.1186/s13613-020-00724-1
Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TSA, Al Mamun A, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data. Lancet Respir Med 2014;2:395-404. https://doi.org/10.1016/S2213-2600(14)70041-4
McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clinical Infectious Diseases 2007;45:1568-75. https://doi.org/10.1086/523584
Lee N, Choi KW, Chan PKS, Hui DSC, Lui GCY. Outcomes of adults hospitalised with severe influenza. 2024. https://doi.org/10.1136/thx.2009.130799
Tenforde MW, Noah KP, O'Halloran AC, Kirley PD, Hoover C, Alden NB, et al. Timing of Influenza Antiviral Therapy and Risk of Death in Adults Hospitalized With Influenza-Associated Pneumonia, Influenza Hospitalization Surveillance Network (FluSurv-NET), 2012-2019. Clinical Infectious Diseases 2025;80:461-8. https://doi.org/10.1093/cid/ciae427
Qiao M, Moyes G, Zhu F, Li Y, Wang X. The prevalence of influenza bacterial co-infection and its role in disease severity: A systematic review and metaanalysis. J Glob Health 2023;13. https://doi.org/10.7189/jogh.13.04063
Arranz-Herrero J, Presa J, Rius-Rocabert S, Utrero-Rico A, Arranz-Arija JA, Lalueza A, et al. Determinants of poor clinical outcome in patients with influenza pneumonia: A systematic review and meta-analysis. International Journal of Infectious Diseases 2023;131:173-9. https://doi.org/10.1016/j.ijid.2023.04.003
Beumer MC, Koch RM, van Beuningen D, OudeLashof AM, van de Veerdonk FL, Kolwijck E, et al. Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality. J Crit Care 2019;50:59-65. https://doi.org/10.1016/j.jcrc.2018.11.013
Carmichael H, Asch SM, Bendavid E. Clostridium difficile and other adverse events from overprescribed antibiotics for acute upper respiratory infection. J Intern Med 2023;293:470-80. https://doi.org/10.1111/joim.13597
Zuttion MSSR, Parimon T, Bora SA, Yao C, Lagree K, Gao CA, et al. Antibiotic use during influenza infection augments lung eosinophils that impair immunity against secondary bacterial pneumonia. Journal of Clinical Investigation 2024;134:e180986. https://doi.org/10.1172/JCI180986
Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clinical Microbiology and Infection 2020;26:1622-9. https://doi.org/10.1016/j.cmi.2020.07.016
Shah MM, Patel K, Milucky J, Taylor CA, Reingold A, Armistead I, et al. Bacterial and viral infections among adults hospitalized with COVID-19, COVID-NET, 14 states, March 2020-April 2022. Influenza Other Respir Viruses 2023;17. https://doi.org/10.1111/irv.13107
Hedberg P, Johansson N, Ternhag A, Abdel-Halim L, Hedlund J, Naucler P. Bacterial co-infections in community-acquired pneumonia caused by SARS-CoV-2, influenza virus and respiratory syncytial virus. BMC Infect Dis 2022;22. https://doi.org/10.1186/s12879-022-07089-9
Metzger DW, Sun K. Immune Dysfunction and Bacterial Coinfections following Influenza. The Journal of Immunology 2013;191:2047-52. https://doi.org/10.4049/jimmunol.1301152
Metlay JP, Fine MJ, Schutz R, Marrie TJ, Cotey CM, Kapoor WN, et al. Measuring Symptomatic and Functional Recovery in Patients with Community-Acquired Pneumonia. vol. 12. 1997. https://doi.org/10.1046/j.1525-1497.1997.00074.x
Macdonald C, Jayathissa S, Leadbetter M. Is post-pneumonia chest X-ray for lung malignancy useful? Results of an audit of current practice. Intern Med J 2015;45:329-34. https://doi.org/10.1111/imj.12699
Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2024-25 Influenza Season. 2024. https://doi.org/10.15585/mmwr.mm7432a2
Kobayashi M, Spiller MW, Wu X, Wang R, Chillarige Y, Wernecke M, et al. Association of Pneumococcal Conjugate Vaccine Use with Hospitalized Pneumonia in Medicare Beneficiaries 65 Years or Older with and Without Medical Conditions, 2014 to 2017. JAMA Intern Med 2023;183:40-7. https://doi.org/10.1001/jamainternmed.2022.5472
Colombo L, Hadigal S, Nauta J, Kondratenko A, Rogoll J, Van de Witte S. Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity. Expert Rev Vaccines 2024;23:88-101. https://doi.org/10.1080/14760584.2023.2293241
Jaramillo Martinez GA, Urrego Rodriguez JH, Martinez Saldarriaga LA, Gonzalez Parra G, Rojas Fernandez GR, Velasco Hernandez BX, et al. Lineamientos técnicos y operativos para la vacunación contra la influenza estacional cepa sur 2024. Ministerio de Salud y Protección Social 2024.
Jamotte A, Caicedo Navas A, Macabeo B, Lopez J, Romero M, Marrugo R, et al. Public Health and Economic Benefits of Quadrivalent Influenza Vaccine in Colombia. Value in Health 2015;18:A590. https://doi.org/10.1016/j.jval.2015.09.1514
Coleman BL, Gutmanis I, McGovern I, Haag M. Effectiveness of CellBased Quadrivalent Seasonal Influenza Vaccine: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2023;11:1607. https://doi.org/10.3390/vaccines11101607
Staying Up to Date with COVID-19 Vaccines | COVID-19 | CDC n.d. https://www.cdc.gov/covid/vaccines/stay-up-to-date.html?utm_source=chatgpt.com (accessed September 29, 2025).
COVID-19 Vaccines Advice n.d. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice?utm_source=chatgpt.com (accessed September 29, 2025).
Link-Gelles R, Chickery S, Webber A, Ong TC, Rowley EAK, DeSilva MB, et al. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged >18 Years - VISION and IVY Networks, September 2024 January 2025. MMWR Morb Mortal Wkly Rep 2025;74:73-82. https://doi.org/10.15585/mmwr.mm7406a1
Havers FP, Whitaker M, Chatwani B, Patton ME, Taylor CA, Chai SJ, et al. COVID 19 Associated Hospitalizations and Maternal Vaccination Among Infants Aged 6 Months COVIDNET, 12 States, October 2022- April 2024. MMWR Morb Mortal Wkly Rep 2024;73:830-6. https://doi.org/10.15585/mmwr.mm7338a1
An Evidence-Based Approach to Covid-19 Vaccination. New England Journal of Medicine 2025. https://doi.org/10.1056/NEJMc2507760
Informe GOLD 2024 - Iniciativa global para la enfermedad pulmonar obstructiva crónica - GOLD n.d. https://goldcopd.org/2024-gold-report/ (accessed October 6, 2025).
Papi A, Ison MG, Langley JM, Lee D-G, Leroux-Roels I, Martinon-Torres F, et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. New England Journal of Medicine 2023;388:595-608. https://doi.org/10.1056/NEJMoa2209604
Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023;72:793-801. https://doi.org/10.15585/mmwr.mm7229a4
Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, et al. Use of Respiratory Syncytial Virus Vaccines in Adults Aged >60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:696-702. https://doi.org/10.15585/mmwr.mm7332e1
Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. vol. 73. 2024. https://doi.org/10.15585/mmwr.mm7336a3
Kobayashi M, Leidner AJ, Gierke R, Xing W, Accorsi E, Moro P, et al. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged >50 Years: Recommendations of the Advisory Committee on Immunization Practices-United States, 2024. 2025. https://doi.org/10.15585/mmwr.mm7401a1
Introduction of pneumococcal vaccine PCV13, A handbook for district and health facility staff World Health Organization. 2013.
Lazarus R, Clutterbuck E, Yu LM, Bowman J, Bateman EA, Diggle L, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clinical Infectious Diseases 2011;52:736-42. https://doi.org/10.1093/cid/cir003
Calendarios Vacunales de la Sociedad Colombiana de Pediatría - Versión 1 año 2024 by Sociedad Colombiana de Pediatría - Issuu n.d. https://issuu.com/precopscp/docs/calendarios_vacunales_de_la_sociedad_colombiana_de (accessed October 6, 2025).
Kricorian K, Civen R, Equils O. COVID-19 vaccine hesitancy: misinformation and perceptions of vaccine safety. Hum Vaccin Immunother 2022;18. https://doi.org/10.1080/21645515.2021.1950504
Acuti Martellucci C, Rosso A, Zauli E, Bianconi A, Fiore M, Soldato G, et al. The Effectiveness of Four Quadrivalent, Inactivated Influenza Vaccines Administered Alone or in Combination with Pneumococcal and/or SARS-CoV-2 Vaccines: A Population-Wide Cohort Study. Vaccines (Basel) 2025;13. https://doi.org/10.3390/vaccines13030309